North Immunology is going public through a reverse merger with Aethlon Medical, a deal that provides $180M to advance its lead eczema drug toward the clinic. The company focuses on inflammation and immunology, with atopic dermatitis as the lead indication for its dual-acting antibody candidate.
All three sources agree on the core facts: the reverse merger, the $180M financing, and the eczema program. They differ mainly in emphasis. MedCity News notes that North Immunology aims to show its bispecific antibody offers efficacy and tolerability advantages over Sanofi's immune disorder juggernaut. BioPharma Dive, by contrast, frames the deal as part of a sudden spike in reverse mergers, driven by a change in sentiment across the biotech sector.
Fierce Biotech offers the simplest description, saying the drug is heading toward the clinic. Taken together, the coverage paints a picture of a startup using a faster public-market route to fund a next-generation inflammation therapy while the reverse merger window is open.